VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
- Conditions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Vical
- Target Recruit Count
- 4
- Registration Number
- NCT03327727
- Locations
- 🇺🇸
University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham, Alabama, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento, California, United States
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
- Conditions
- Interventions
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Vical
- Target Recruit Count
- 261
- Registration Number
- NCT02837575
- Locations
- 🇺🇸
QPS Broward Research, Hollywood, Florida, United States
🇺🇸Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Vical
- Target Recruit Count
- 165
- Registration Number
- NCT02030301
- Locations
- 🇺🇸
Alabama Vaccine Research Clinic, Birmingham, Alabama, United States
🇺🇸Westover Heights Clinic, Portland, Oregon, United States
🇺🇸Broward Research Group, Hollywood, Florida, United States
Pandemic Influenza Plasmid DNA Vaccines (Needle)
- Conditions
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Vical
- Target Recruit Count
- 56
- Registration Number
- NCT00709800
- Locations
- 🇺🇸
Accelovance, San Diego, California, United States
🇺🇸SNBL, Baltimore, Maryland, United States
🇺🇸SUNY at Stonybrook, Stony Brook Medical Center, Stony Brook, New York, United States
Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)
- Conditions
- Interventions
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Vical
- Target Recruit Count
- 47
- Registration Number
- NCT00694213
- Locations
- 🇺🇸
Accelovance, San Diego, California, United States
🇺🇸SNBL, Baltimore, Maryland, United States
🇺🇸SUNY at Stonybrook, Stony Brook Medical Center, Stony Brook, New York, United States
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
- Conditions
- Interventions
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Vical
- Target Recruit Count
- 390
- Registration Number
- NCT00395070
- Locations
- 🇺🇸
Location #23, Cleveland, Ohio, United States
🇺🇸Location #117, Houston, Texas, United States
🇺🇸Location #32, Seattle, Washington, United States
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Vical
- Target Recruit Count
- 26
- Registration Number
- NCT00223899
- Locations
- 🇺🇸
Location #4, Montclair, New Jersey, United States
🇺🇸Location #2, Mobile, Alabama, United States
🇺🇸Location #3, Denver, Colorado, United States
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2011-07-07
- Lead Sponsor
- Vical
- Target Recruit Count
- 78
- Registration Number
- NCT00003646
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Physician Reliance Network, Inc., Dallas, Texas, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2008-07-25
- Lead Sponsor
- Vical
- Registration Number
- NCT00003647
- Locations
- 🇺🇸
Oncology and Hematology Associates, Westwood, Kansas, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer
- First Posted Date
- 2003-11-04
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Vical
- Target Recruit Count
- 25
- Registration Number
- NCT00005072
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States